- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03414866
Thoraflex Hybrid Post-Market Study (THOR)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aortic arch pathologies are rare, but pose significant challenges for treatment involving open surgical or endovascular repair.
In 1983 the Elephant Trunk technique was introduced and has greatly facilitated the management of patients with extensive thoracic aortic disease.
In recent years, this traditional open surgery has been combined with thoracic endovascular repair (TEVAR) and this is known as the 'hybrid' approach. Hybrid repairs, consisting of an open surgical repair combined with endovascular techniques.
Further advancement in the types of prosthesis available has resulted in the evolution of the conventional ET technique into the frozen elephant trunk (FET) technique. This utilises devices that incorporate both a traditional dacron graft (for open surgical treatment of the aortic arch) and a stented graft portion (for treatment of the descending thoracic aorta). The stented portion of the graft is introduced via an antegrade approach through the transected arch. The FET technique is now commonly used to treat patients with extensive thoracic or thoraco-abdominal aortic disease.
Vascutek Ltd has developed the Thoraflex™ Hybrid Device (Plexus™ 4 and Ante-Flo™) for the repair or replacement of damaged or diseased vessels of the ascending aorta, aortic arch and descending thoracic aorta in cases of aneurysm and/or dissection. The Thoraflex™ Hybrid Device is one of the commercially available frozen elephant trunk prosthesis.
Over 3000 Thoraflex™ Hybrid Devices have been sold and the current study seeks to provide further evidence of the continuing safety and effectiveness of the device.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre, University Hospital
-
Ottawa, Ontario, Canada
- University of Ottawa Heart Institute
-
Toronto, Ontario, Canada
- Toronto General Hospital
-
-
-
-
-
Freiburg, Germany
- University of Freiburg
-
Hanover, Germany, 30625
- Hannover Medical School
-
-
-
-
-
Bologna, Italy
- Policlinico S.Orsola-Malpighi
-
-
-
-
-
Nieuwegein, Netherlands
- St Antonious Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
60 patients with acute thoracic aortic syndrome, including: acute dissection, aortic rupture and penetrating aortic ulcer (PAU)
60 patients with a subacute/chronic dissection of the aorta
60 patients with an aortic aneurysm
Description
Inclusion Criteria:
- Patient is aged 18 years or over on date of consent
- Patient is willing and able to comply with all study procedures and study visits
- Patient or their legally authorised representative (LAR) has given written informed consent to participate in study. For emergency patients only, retrospective consent is permissible
- Patient satisfies the inclusion criteria for one of the following categories:
A - Patient has acute thoracic aortic syndrome or B - Patient has subacute/ chronic dissection of the aorta or C - Patient has an aortic aneurysm (including connective tissue disorders)
A. Patients with acute thoracic aortic syndrome:
Patient has acute thoracic aortic syndrome and requires repair or replacement of damaged or diseased vessels of the aortic arch (with or without involvement of the ascending aorta), and the descending aorta requires replacement, or, in the opinion of the investigator, the patient would derive clinical benefit from prophylactic treatment of the descending aorta. This includes patients with acute dissections, rupture of the aorta or PAU.
B. Patients with subacute/chronic dissection of the aorta:
- Patient requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta due to subacute/chronic dissection.
And patient satisfies one or more of the following criteria:
- Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥5.5cm (including if asymptomatic) or
- Patient has aorta diameter <5.5cm and growth rate ≥0.5cm/year (including if asymptomatic) or
- Patient has ascending aorta diameter ≥4.5cm and requires valve repair or replacement
C. Patients with an aortic aneurysm (including connective tissue disorders):
- Patient requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta
And patient satisfies one or more of the following criteria:
- Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥5.5cm (including if asymptomatic) or
- Patient has aorta diameter <5.5cm and growth rate ≥0.5cm/year (including if asymptomatic) or
- Patient has ascending aorta diameter ≥4.5cm and requires valve repair or replacement.
or
- Patient has Marfan syndrome or other genetically mediated disorders with aortic sinus, or ascending aorta, or arch diameter ≥4.5cm, or, the ratio of the maximal ascending or aortic root area (Π r2) in cm2 divided by the patient's height in meters exceeds 10
Exclusion Criteria:
- Patient is unfit for open surgical repair involving circulatory arrest
- Patient has known sensitivity to polyester, nitinol or materials of bovine origin
- Patient has active endocarditis or an active infective disorder of the aorta
- Patient has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure
- Patient is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study, which in the opinion of the Investigator will impact on this study
- Patient has an uncorrectable bleeding anomaly
- Patient has renal failure (defined as dialysis dependent)
- Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated
- Patient has a co-morbidity causing expected survival to be less than 1 year
- Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Acute thoracic aortic syndrome
60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
|
Written questionnaire
|
Subacute/chronic dissection of the aorta
60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
|
Written questionnaire
|
Aortic aneurysm
60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
|
Written questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from Major Adverse Event
Time Frame: 1 year post-procedure
|
The primary endpoint will be freedom from the following composite Major Adverse Event (MAE): permanent stroke , permanent paraplegia/paraparesis, unanticipated aortic related re-operation (excluding re-operation for bleeding) and aortic related mortality
|
1 year post-procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Malakh Shrestha, Prof. Dr., Hannover Medical School
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Wounds and Injuries
- Aortic Diseases
- Aneurysm, Ruptured
- Dissection, Blood Vessel
- Acute Aortic Syndrome
- Rupture
- Aneurysm
- Aortic Aneurysm
- Aortic Aneurysm, Thoracic
- Aortic Rupture
- Aortic Dissection
- Penetrating Atherosclerotic Ulcer
Other Study ID Numbers
- THOR-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Dissection
-
Centre Cardiologique du NordUniversita degli Studi di Genova; Henri Mondor University Hospital; Pitié-Salpêtrière...Enrolling by invitationAortic Valve Insufficiency | Aortic Diseases | Ascending Aortic Dissection | Aortic Arch | Aortic Root Dissection | Aortic Root Dilatation | Type A Aortic DissectionFrance
-
Assiut UniversityRecruitingAortic Root Aneurysm | Aortic Root DissectionEgypt
-
The University of Texas Health Science Center,...RecruitingACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy (ACUTE-B)Distal Aortic Dissection | Dissection, Aortic Acute | Acute Type B Aortic Dissection (Uncomplicated)United States
-
Petrovsky National Research Centre of SurgeryRecruitingThoracic Aortic Aneurysm | Thoracic Aortic Dissection | Cardiac Valve Disease | Aortic Aneurysm and DissectionRussian Federation
-
University of PennsylvaniaBolton MedicalEnrolling by invitationThoracic Aortic Aneurysm | Thoracic Aortic Dissection | MicroemboliUnited States
-
The University of Texas Health Science Center,...Washington University School of Medicine; University of Michigan; John Ritter...Active, not recruiting
-
Braile Biomedica Ind. Com. e Repr. Ltda.RecruitingThoracic Aortic DissectionBrazil
-
IRCCS San RaffaeleNot yet recruitingAneurysm | Aortic Arch | Dissection, Aortic
-
Jakob Stensballe, MD, PhDCellphire Therapeutics, Inc.Completed
-
University Hospital, Basel, SwitzerlandRecruitingThoracic Aortic Aneurysm | Acute Aortic DissectionSwitzerland
Clinical Trials on EQ-5D-5L QOL questionnaire
-
University Hospital, ToulouseNot yet recruiting
-
Hamilton Health Sciences CorporationRecruiting
-
RenJi HospitalNot yet recruitingLocalized Prostate Cancer
-
Ramsay Générale de SantéRecruitingTerminal Renal InsufficiencyFrance
-
Chinese University of Hong KongUnknownCOVID-19 | Quality of Life
-
University Hospital, Basel, SwitzerlandCompletedGynecologic Cancer | Gynecologic DiseaseSwitzerland
-
The University of Hong KongCompletedQuality of Life | Musculoskeletal Disease | OutcomeHong Kong
-
University of LiegeCompletedCritical Illness | Covid19 | Psychological Stress | FamilyBelgium
-
Canadian Cancer Trials GroupCanadian Institutes of Health Research (CIHR)RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaCanada
-
Hospices Civils de LyonNot yet recruiting